New perspectives in the diagnosis of hepatitis C

Eugene R Schiff, Maria De Medina, Rizwana S. Kahn

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Since the identification and molecular characterization of the non-A, non-B hepatitis virus (HCV) in 1989, a variety of diagnostic tests based on the detection of hepatitis virus antibodies or HCV RNA in the serum have been developed and refined. The enzyme-linked immunosorbent assays (ELISAs) and the recombinant immunoblot assays (RIBAs) exhibit improved sensitivity and specificity for HCV antibodies compared with their predecessors, and the ELISA-3 is at the forefront of HCV screening. Furthermore, the advent of molecular assays that employ quantitative reverse-transcriptase polymerase chain reaction to detect HCV RNA has allowed clinicians to track the natural history of HCV and to monitor the progress of therapy. A role for further refinement of an HCV diagnosis using tests to determine genotype, subtype, and quasispecies is explored. In addition, the role of liver biopsy and noninvasive markers of histologic status are placed into the context of patient prognosis. This article reviews the state-of-the-art tests and assays developed for the diagnosis and management of HCV infection.

Original languageEnglish
Pages (from-to)3-16
Number of pages14
JournalSeminars in Liver Disease
Volume19
Issue number1 SUPPL. 1
StatePublished - May 20 1999

Fingerprint

Hepatitis Viruses
Hepatitis C
Hepatitis Antibodies
Enzyme-Linked Immunosorbent Assay
RNA
Hepatitis C Antibodies
Natural History
Reverse Transcriptase Polymerase Chain Reaction
Routine Diagnostic Tests
Genotype
Biopsy
Sensitivity and Specificity
Liver
Infection
Serum
Therapeutics

Keywords

  • Chronic hepatitis C
  • Diagnosis
  • Enzyme-linked immunosorbent assay
  • Recombinant immunoblot assay
  • Reverse-transcriptase polymerase chain reaction

ASJC Scopus subject areas

  • Hepatology

Cite this

Schiff, E. R., De Medina, M., & Kahn, R. S. (1999). New perspectives in the diagnosis of hepatitis C. Seminars in Liver Disease, 19(1 SUPPL. 1), 3-16.

New perspectives in the diagnosis of hepatitis C. / Schiff, Eugene R; De Medina, Maria; Kahn, Rizwana S.

In: Seminars in Liver Disease, Vol. 19, No. 1 SUPPL. 1, 20.05.1999, p. 3-16.

Research output: Contribution to journalArticle

Schiff, ER, De Medina, M & Kahn, RS 1999, 'New perspectives in the diagnosis of hepatitis C', Seminars in Liver Disease, vol. 19, no. 1 SUPPL. 1, pp. 3-16.
Schiff ER, De Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Seminars in Liver Disease. 1999 May 20;19(1 SUPPL. 1):3-16.
Schiff, Eugene R ; De Medina, Maria ; Kahn, Rizwana S. / New perspectives in the diagnosis of hepatitis C. In: Seminars in Liver Disease. 1999 ; Vol. 19, No. 1 SUPPL. 1. pp. 3-16.
@article{3e3f075268d64f799cbff1784b7ed7c6,
title = "New perspectives in the diagnosis of hepatitis C",
abstract = "Since the identification and molecular characterization of the non-A, non-B hepatitis virus (HCV) in 1989, a variety of diagnostic tests based on the detection of hepatitis virus antibodies or HCV RNA in the serum have been developed and refined. The enzyme-linked immunosorbent assays (ELISAs) and the recombinant immunoblot assays (RIBAs) exhibit improved sensitivity and specificity for HCV antibodies compared with their predecessors, and the ELISA-3 is at the forefront of HCV screening. Furthermore, the advent of molecular assays that employ quantitative reverse-transcriptase polymerase chain reaction to detect HCV RNA has allowed clinicians to track the natural history of HCV and to monitor the progress of therapy. A role for further refinement of an HCV diagnosis using tests to determine genotype, subtype, and quasispecies is explored. In addition, the role of liver biopsy and noninvasive markers of histologic status are placed into the context of patient prognosis. This article reviews the state-of-the-art tests and assays developed for the diagnosis and management of HCV infection.",
keywords = "Chronic hepatitis C, Diagnosis, Enzyme-linked immunosorbent assay, Recombinant immunoblot assay, Reverse-transcriptase polymerase chain reaction",
author = "Schiff, {Eugene R} and {De Medina}, Maria and Kahn, {Rizwana S.}",
year = "1999",
month = "5",
day = "20",
language = "English",
volume = "19",
pages = "3--16",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - New perspectives in the diagnosis of hepatitis C

AU - Schiff, Eugene R

AU - De Medina, Maria

AU - Kahn, Rizwana S.

PY - 1999/5/20

Y1 - 1999/5/20

N2 - Since the identification and molecular characterization of the non-A, non-B hepatitis virus (HCV) in 1989, a variety of diagnostic tests based on the detection of hepatitis virus antibodies or HCV RNA in the serum have been developed and refined. The enzyme-linked immunosorbent assays (ELISAs) and the recombinant immunoblot assays (RIBAs) exhibit improved sensitivity and specificity for HCV antibodies compared with their predecessors, and the ELISA-3 is at the forefront of HCV screening. Furthermore, the advent of molecular assays that employ quantitative reverse-transcriptase polymerase chain reaction to detect HCV RNA has allowed clinicians to track the natural history of HCV and to monitor the progress of therapy. A role for further refinement of an HCV diagnosis using tests to determine genotype, subtype, and quasispecies is explored. In addition, the role of liver biopsy and noninvasive markers of histologic status are placed into the context of patient prognosis. This article reviews the state-of-the-art tests and assays developed for the diagnosis and management of HCV infection.

AB - Since the identification and molecular characterization of the non-A, non-B hepatitis virus (HCV) in 1989, a variety of diagnostic tests based on the detection of hepatitis virus antibodies or HCV RNA in the serum have been developed and refined. The enzyme-linked immunosorbent assays (ELISAs) and the recombinant immunoblot assays (RIBAs) exhibit improved sensitivity and specificity for HCV antibodies compared with their predecessors, and the ELISA-3 is at the forefront of HCV screening. Furthermore, the advent of molecular assays that employ quantitative reverse-transcriptase polymerase chain reaction to detect HCV RNA has allowed clinicians to track the natural history of HCV and to monitor the progress of therapy. A role for further refinement of an HCV diagnosis using tests to determine genotype, subtype, and quasispecies is explored. In addition, the role of liver biopsy and noninvasive markers of histologic status are placed into the context of patient prognosis. This article reviews the state-of-the-art tests and assays developed for the diagnosis and management of HCV infection.

KW - Chronic hepatitis C

KW - Diagnosis

KW - Enzyme-linked immunosorbent assay

KW - Recombinant immunoblot assay

KW - Reverse-transcriptase polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=0032953098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032953098&partnerID=8YFLogxK

M3 - Article

C2 - 10349688

AN - SCOPUS:0032953098

VL - 19

SP - 3

EP - 16

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1 SUPPL. 1

ER -